

CADTH RAPID RESPONSE REPORT: REFERENCE LIST

# Positron Emission Tomography–Computed Tomography for Patients with Suspected or Confirmed Coronary Artery Disease: Clinical Utility, Cost- Effectiveness, and Diagnostic Accuracy

Service Line: Rapid Response Service  
Version: 1.0  
Publication Date: October 9, 2020  
Report Length: 8 Pages

**Authors:** Diksha Kumar, Charlene Argáez

**Cite As:** *Positron Emission Tomography–Computed Tomography for Patients with Suspected or Confirmed Coronary Artery Disease: Clinical Utility, Cost-Effectiveness, and Diagnostic Accuracy*. Ottawa: CADTH; 2020 Oct. (CADTH rapid response report: reference list).

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to [requests@cadth.ca](mailto:requests@cadth.ca)

## Research Questions

1. What is the clinical utility of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve?
2. What is the cost-effectiveness of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve?
3. What is the clinical evidence regarding the safety of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve?
4. What is the diagnostic accuracy of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve?

## Key Findings

One randomized controlled trial and one non-randomized study were identified regarding the clinical utility of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve. In addition, three systematic reviews (two with meta-analyses) and 14 non-randomized studies were identified regarding the diagnostic accuracy of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve. One of the non-randomized studies also addressed the safety of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve. No relevant literature was identified regarding the cost-effectiveness of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve.

## Methods

### Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including Medline and EMBASE via OVID, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were positron emission tomography computed tomography (PET/CT), and coronary artery disease. No filters were applied to limit the retrieval by study type. The search was also limited to English language documents published between January 1, 2010 and September 24, 2020. Internet links are provided where available.

### Selection Criteria

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in Table 1. Full texts of study publications were not reviewed.

**Table 1: Selection Criteria**

<b>Population</b>	Patients with suspected or confirmed coronary artery disease or acute coronary syndrome (unstable angina) with cardiac perfusion abnormalities or myocardial ischemia
<b>Intervention</b>	PET–CT or PET for the detection of cardiac perfusion and coronary flow reserve (Q4: Reference test: FFR or measurement of coronary flow reserve during invasive angiography)
<b>Comparator</b>	Q1-2: SPECT; Invasive angiography Q3-4: SPECT; No comparator (Q4: FFR or measurement of coronary flow reserve during invasive angiography)
<b>Outcomes</b>	Q1: Clinical utility: detecting cardiac perfusion (based on coronary flow reserve) to determine clinical decisions such as pharmaceutical treatment, coronary artery bypass surgery, coronary artery stents/ revascularization; hospitalization; mortality Q2: Cost-effectiveness Q3: Safety (e.g., radiation dose/exposure) Q4: Diagnostic accuracy: sensitivity, specificity, accuracy, positive predictive value, negative predictive value, cardiac perfusion detection rate
<b>Study Designs</b>	Health technology assessment, systematic reviews, randomized controlled trials, non-randomized studies, economic evaluations

FFR = fractional flow reserve; PET = positron emission tomography; PET-CT = positron emission tomography – computed tomography; SPECT = single-photon emission computed tomography

## Results

One randomized controlled trial<sup>4</sup> and one non-randomized study<sup>5</sup> were identified regarding the clinical utility of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve. In addition, three systematic reviews<sup>1-3</sup> (two with meta-analyses<sup>1,2</sup>) and 14 non-randomized studies<sup>6-19</sup> were identified regarding the diagnostic accuracy of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve. One of the non-randomized studies<sup>6</sup> also addressed the safety of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve. No health technology assessments or economic evaluations were identified.

Additional references of potential interest that did not meet the inclusion criteria are provided in the appendix.

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-Analyses

#### *Diagnostic Accuracy*

1. Jaarsma C, Leiner T, Bekkers SC, et al. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis. *J Am Coll Cardiol.* 2012 May 8;59(19):1719-1728.  
[PubMed: PM22554604](https://pubmed.ncbi.nlm.nih.gov/22554604/)

2. Parker MW, Iskandar A, Limone B, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: a bivariate meta-analysis. *Circ Cardiovasc Imaging*. 2012 Nov;5(6):700-707.  
[PubMed: PM23051888](#)
3. Al Moudi M, Sun Z, Lenzo N. Diagnostic value of SPECT, PET and PET/CT in the diagnosis of coronary artery disease: a systematic review. *Biomed Imaging Interv J*. 2011 Apr;7(2):e9.  
[PubMed: PM22287989](#)

## Randomized Controlled Trials

### *Clinical Utility*

4. Patel KK, Al Badarin F, Chan PS, et al. Randomized comparison of clinical effectiveness of pharmacologic SPECT and PET MPI in symptomatic CAD patients. *JACC Cardiovasc Imaging*. 2019 Sep;12(9):1821-1831.  
[PubMed: PM31326480](#)

## Non-Randomized Studies

### *Clinical Utility*

5. Knight S, Min DB, Le VT, et al. Implementation of a cardiac PET stress program: Comparison of outcomes to the preceding SPECT era. *JCI Insight*. 2018 May;3(9):e120949.  
[PubMed: PM29720565](#)

### *Diagnostic Accuracy and Safety*

6. Maddahi J, Lazewatsky J, Udelson JE, et al. Phase-III clinical trial of fluorine-18 flurpiridaz positron emission tomography for evaluation of coronary artery disease. *J Am Coll Cardiol*. 2020 28 July;76(4):391-401.  
[PubMed: PM32703509](#)

### *Diagnostic Accuracy*

7. Acampa W, Zampella E, Assante R, et al. Quantification of myocardial perfusion reserve by CZT-SPECT: a head to head comparison with 82 Rubidium PET imaging. *J Nucl Cardiol*. 2020 May 7.  
[PubMed: PM32383083](#)
8. Bendix K, Thomassen A, Junker A, Veien KT, Jensen LO. 15 O-water positron emission tomography of myocardial ischemia in patients referred for percutaneous coronary intervention. *Cardiovasc Revasc Med*. 2020 Mar 7;S1553-8389(20)30142-1.  
[PubMed: PM32247563](#)
9. Hyafil F, Chequer R, Sorbets E, et al. Head-to-head comparison of the diagnostic performances of Rubidium-PET and SPECT with CZT camera for the detection of myocardial ischemia in a population of women and overweight individuals. *J Nucl Cardiol*. 2020 01 Jun;27(3):755-768.  
[PubMed: PM30574676](#)

10. Fathala A, Aboulkheir M, Shoukri MM, Alsergani H. Diagnostic accuracy of (13)N-ammonia myocardial perfusion imaging with PET-CT in the detection of coronary artery disease. *Cardiovasc Diagn Ther.* 2019 Feb;9(1):35-42.  
[PubMed: PM30881875](#)
11. Brophey MD, Farukhi IM, Castanon R, DeLaPena R, Bradshaw L, Banerjee S. Accuracy of (82)Rb PET/CT myocardial perfusion imaging with regadenoson stress, including 3-year clinical outcomes. *J Nucl Med Technol.* 2017 Jun;45(2):75-81.  
[PubMed: PM28408703](#)
12. Danad I, Raijmakers PG, Driessen RS, et al. Comparison of coronary CT angiography, SPECT, PET, and hybrid imaging for diagnosis of ischemic heart disease determined by fractional flow reserve. *JAMA Cardiol.* 2017 Oct;2(10):1100-1107.  
[PubMed: PM28813561](#)
13. Dou KF, Gao XJ, Xie BQ, Li Y, He ZX, Yang MF. Dual-time-point myocardial (18)F-FDG imaging in the detection of coronary artery disease. *BMC Cardiovasc Disord.* 2017 May 10;17(1):120.  
[PubMed: PM28490354](#)
14. Dou KF, Xie BQ, Gao XJ, et al. Use of resting myocardial 18F-FDG imaging in the detection of unstable angina. *Nucl Med Commun.* 2015 Oct;36(10):999-1006.  
[PubMed: PM26225939](#)
15. Al Moudi M, Sun ZH. Diagnostic value of (18)F-FDG PET in the assessment of myocardial viability in coronary artery disease: a comparative study with (99m)Tc SPECT and echocardiography. *J Geriatr Cardiol.* 2014 Sep;11(3):229-236.  
[PubMed: PM25278972](#)
16. Berman DS, Maddahi J, Tamarappoo BK, et al. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. *J Am Coll Cardiol.* 2013 Jan 29;61(4):469-477.  
[PubMed: PM23265345](#)
17. Hsiao E, Ali B, Blankstein R, et al. Detection of obstructive coronary artery disease using regadenoson stress and 82Rb PET/CT myocardial perfusion imaging. *J Nucl Med.* 2013 Oct;54(10):1748-1754.  
[PubMed: PM23940305](#)
18. Nakazato R, Berman DS, Dey D, et al. Automated quantitative Rb-82 3D PET/CT myocardial perfusion imaging: normal limits and correlation with invasive coronary angiography. *J Nucl Cardiol.* 2012 Apr;19(2):265-276.  
[PubMed: PM22203445](#)
19. Kajander S, Joutsiniemi E, Saraste M, et al. Cardiac positron emission tomography/computed tomography imaging accurately detects anatomically and functionally significant coronary artery disease. *Circulation.* 2010 Aug 10;122(6):603-613.  
[PubMed: PM20660808](#)

## Economic Evaluations

No literature identified.

## Appendix — Further Information

### Previous CADTH Reports

20. Smith A, Loshak H. PET-CT for cardiology: a rapid qualitative evidence synthesis of patients' and caregivers' perspectives and experiences [*CADTH rapid response report: summary with critical appraisal*]. Ottawa (ON): CADTH; 2019 Mar; <https://cadth.ca/sites/default/files/pdf/htis/2019/RC1081%20PET-CT%20for%20Cardiology%20Final.pdf> Accessed 2020 Oct 08.
21. Pejic W, Ford C, Argáez C. Positron emission tomography–computed tomography for cardiovascular indications: diagnostic accuracy, clinical utility, cost-effectiveness, and guidelines [*CADTH rapid response report: summary of abstracts*]. Ottawa (ON): CADTH; 2018 Aug; <https://www.cadth.ca/sites/default/files/pdf/htis/2018/RB1244%20PET-CT%20for%20Cardiovascular%20Indications%20Final.pdf> Accessed 2020 Oct 08
22. Mujoomdar M, Clark M, Nkansah E. Positron emission tomography for cardiovascular disease: a review of the clinical effectiveness [*CADTH rapid response report: peer reviewed summary with critical appraisal*]. Ottawa (ON): CADTH; 2010 Aug; [https://cadth.ca/sites/default/files/pdf/M0015\\_PET\\_for\\_Cardiology\\_e.pdf](https://cadth.ca/sites/default/files/pdf/M0015_PET_for_Cardiology_e.pdf) Accessed 2020 Oct 08.

### Non-Randomized Studies

#### *Clinical Utility – Mixed Comparator*

23. Ma Q, Sridhar G, Power T, Agiro A. Assessing the downstream value of first-line cardiac positron emission tomography (PET) imaging using real world Medicare fee-for-service claims data. *J Nucl Cardiol*. 2019 Dec 9. [PubMed: PM31820411](#)

#### *Diagnostic Accuracy – Alternative Comparator*

24. Thomassen A, Braad PE, Pedersen KT, et al. 15-O-water myocardial flow reserve PET and CT angiography by full hybrid PET/CT as a potential alternative to invasive angiography. *Int J Cardiovasc Imaging*. 2018 Dec;34(12):2011-2022. [PubMed: PM30066164](#)
25. Thomassen A, Petersen H, Diederichsen AC, et al. Hybrid CT angiography and quantitative 15O-water PET for assessment of coronary artery disease: comparison with quantitative coronary angiography. *Eur J Nucl Med Mol Imaging*. 2013 Dec;40(12):1894-1904. [PubMed: PM23982453](#)

#### *Diagnostic Accuracy – Unclear Outcomes*

26. Plass A, Emmert MY, Gaemperli O, et al. The potential value of hybrid positron emission tomography/dual-source computed tomography imaging in coronary bypass surgery. *Heart Surg Forum*. 2011 Oct;14(5):E283-290. [PubMed: PM21997649](#)

#### Unclear Abstract

27. Srivatsava MK, Indirani M, Sathyamurthy I, Sengottuvelu G, Jain AS, Shelley S. Role of PET-CT in the assessment of myocardial viability in patients with left ventricular dysfunction. *Indian Heart J.* 2016 Sep-Oct;68(5):693-699.  
[PubMed: PM27773409](#)
28. Raja S, Singh B, Rohit MK, et al. Comparison of nitrate augmented Tc-99m tetrofosmin gated SPECT imaging with FDG PET imaging for the assessment of myocardial viability in patients with severe left ventricular dysfunction. *J Nucl Cardiol.* 2012 Dec;19(6):1176-1181.  
[PubMed: PM22872319](#)

#### Review Articles

29. Santos BS, Ferreira MJ. Positron emission tomography in ischemic heart disease. *Rev Port Cardiol.* 2019 Aug;38(8):599-608.  
[PubMed: PM31694787](#)
30. Kazakauskaitė E, Žaliaduonytė-Pekšienė D, Rumbinaitė E, Keršulis J, Kulakienė I, Jurkevičius R. Positron emission tomography in the diagnosis and management of coronary artery disease. *Medicina (Kaunas).* 2018 Jul 11;54(3).  
[PubMed: PM30344278](#)

#### Additional Reference

31. Mattison C, Gauvin FP, Wilson MG. Examining the public provision and funding of PET-CT imaging for non-cancer indications: rapid synthesis. Hamilton (ON): McMaster Health Forum, McMaster University; 2018 Feb:  
<https://www.mcmasterforum.org/docs/default-source/product-documents/rapid-responses/examining-the-public-provision-and-funding-of-pet-ct-imaging-for-non-cancer-indications.pdf> Accessed 2020 Oct 08.